Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron
This article was originally published in The Pink Sheet Daily
Executive Summary
More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.